83 reports

  • CLASSIFICATION OF DIABETIC NEUROPATHIES

IT ENROLLED ## PATIENTS, SPLIT INTO SEVEN ARMS, RECEIVING MIROGABALIN ##MG/ DAY, ##MG/ DAY, ##MG/ DAY, ##MG/ DAY, ##MG/ DAY, PREGABALIN ##MG/ DAY, OR PLACEBO, SPLIT IN A ##:##:##:##:##:##:## RATIO.

  • Type 2 Diabetes
  • Forecast
  • Daiichi Sankyo Company
  • Depomed, Inc.
  • Pfizer Inc.

GLP-## IS AN INCRETIN HORMONE THAT IS RELEASED FROM CELLS IN THE GASTROINTESTINAL TRACT INTO THE CIRCULATION IN RESPONSE TO INGESTED NUTRIENTS FROM FOOD.

  • Type 2 Diabetes
  • Southeast Asia
  • Market Size
  • Novo Nordisk Group
  • Sanofi S.A.
  • ASTRAZENECA

These agents are associated with reduced rates of hypoglycemia, moderate and continuous weight loss, and gastrointestinal side effects such as nausea and vomiting.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • 7.1 OVERVIEW

DESPITE ITS LOW COST, GASTROINTESTINAL (GI) SIDE EFFECTS ARE VERY COMMON WITH ACARBOSE, WHICH HAS PREVENTED ITS WIDESPREAD USE.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

Seminars in Diabetologica; ##(##): ##-##.

  • Type 2 Diabetes
  • Allergan plc
  • Clearside Biomedical, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.

Gastrointestinal complications of diabetes.

  • Type 2 Diabetes
  • East Asia
  • North America
  • Northern Europe
  • Scandinavia

JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES; ##(##): ##-##.

  • Type 2 Diabetes
  • United States
  • Conatus Pharmaceuticals Inc.
  • Galectin Therapeutics Inc.
  • Gilead Sciences, Inc.

THE ENDOBARRIER GASTROINTESTINAL LINER IS TRANSORALLY PLACED IN THE GASTROINTESTINAL TRACT IN ORDER TO BYPASS A PORTION OF THE INTESTINE.

  • Type 2 Diabetes
  • United States
  • EnteroMedics Inc.
  • Novo Nordisk Group
  • VIVUS, Inc.

PATIENTS IN THE STANDARD CARE GROUP DEVELOPED CELLULITIS OF THE EFFECTED EXTREMITY (TWO PATIENTS), A GASTROINTESTINAL BLEED (ONE PATIENT), AND ACUTE PYELONEPHRITIS (ONE PATIENT).

  • Type 2 Diabetes
  • FirstString Research, Inc.
  • Organogenesis, Inc.
  • Osiris Therapeutics, Inc.
  • Smith & Nephew Plc
  • Trial Results

Hoffmann-La Roche Ltd. ## ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## ## Mallinckrodt Plc ## ## ## ## ## ## ## ## Pfizer Inc. ## ## ## ## ## ## ## ## Rigel Pharmaceuticals, Inc. ## ## ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## ## ## Cumberland Phar

  • Type 2 Diabetes
  • World
  • Anthera Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Novartis AG

References P##(SHC) Therapeutic Area/ Disease Indications Diabetes Gastrointestinal lesions University of Bari Aldo Moro, Italy.

  • Insulin
  • Type 2 Diabetes
  • United States
  • MC2 Biotek Group
  • POXEL SA
  • PIPELINE BY ELI LILLY AND CO, H2 2018
  • PIPELINE BY LONGEVITY BIOTECH INC, H2 2018

The company' s hybridtide scaffold provides durable protease resistance in biological matrices such as gastrointestinal tract and bloodstream.

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • World
  • Product Initiative

It acts by targeting free fatty acid receptor ## (GPR##).

  • Diabetes
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • GlaxoSmithKline plc
  • Pipeline by Ardelyx Inc, H1 2018

The drug candidate is an agonist of TGR##, a G protein-coupled receptor found in the gastrointestinal (GI) tract.

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • World
  • Product Initiative

WE ARE ALSO ACTIVE IN THE INFECTION, NEUROSCIENCE AND GASTROINTESTINAL (ING) DISEASE AREAS.

  • Type 2 Diabetes
  • Angion Biomedica Corp.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Type 2 Diabetes Mellitus, Global, Pipeline Size by
  • Type 2 Diabetes Mellitus, Global, Key Features of Neuromedin U Receptor 1 (NMUR1), 2018

It can cause significant gastrointestinal and genitourinary problems, and in some cases can lead to erectile dysfunction.

  • Diabetes
  • Insulin
  • Type 2 Diabetes
  • World
  • Deals & Alliance
  • Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Product Development Milestones
  • NOV 04, 2010: ARENA PHARMACEUTICALS PROVIDES UPDATE ON GPR119 PORTFOLIO FOR TYPE 2 DIABETES

GPR## is expressed at high concentrations in the pancreas and gastrointestinal tract.

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • World
  • Product Initiative
  • PIPELINE BY ELI LILLY AND CO, H1 2018

The drug candidate acts by targeting glucagon like peptide ## (GLP-##) and gastric inhibitory polypeptide (GIP).

  • Therapy
  • Type 2 Diabetes
  • United States
  • World
  • Product Initiative
  • RDX-98940 - DRUG PROFILE
  • SMALL MOLECULES TO AGONIZE GLP1 AND GIP RECEPTORS FOR NON ALCOHOLIC STEATOHEPATITIS, OBESITY AND TYPE 2 DIABETES - DRUG PROFILE

IN APRIL ##, 2016, EISAI' S GASTROINTESTINAL DISEASE BUSINESS AND AJINOMOTO PHARMACEUTICALS, WITH AMINO ACIDS AT ITS CORE, WILL BE INTEGRATED AND COMMENCE BUSINESS AS EA PHARMA.

  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative

GPR## is expressed at high concentrations in the pancreas and gastrointestinal tract.

  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • World
  • Product Initiative
  • SAR-425899 - DRUG PROFILE

The patients enrolled in the trial experienced mild to moderate gastrointestinal adverse events at some point.

  • Pharmaceutical
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative
  • 03/05/2018: OZEMPIC now available for Canadians with type 2 diabetes
  • APR 02, 2016: SEMAGLUTIDE DEMONSTRATED SUPERIOR IMPROVEMENTS IN GLYCAEMIC CONTROL VS PLACEBO IN ADULTS WITH TYPE 2 DIABETES

Gastrointestinal adverse events were more frequent in early responders compared with early non -responders (## ##. ## % vs ##. ## %).

  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • United States
  • Novo Nordisk Group

Gastrointestinal disorders were most commonly observed adverse events.

  • Diabetes
  • Obesity
  • Therapy
  • Type 2 Diabetes
  • Omeros Corporation

PXL## is in Phase ## development.

  • Pharmaceutical
  • Type 2 Diabetes
  • Japan
  • Company
  • POXEL SA

WE ARE ALSO ACTIVE IN THE INFECTION, NEUROSCIENCE AND GASTROINTESTINAL (ING) DISEASE AREAS.

  • Type 2 Diabetes
  • United States
  • Amgen Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • TYPE 2 DIABETES - PIPELINE BY SERES THERAPEUTICS INC, H2 2017
  • R&D Progress

Type 2 Diabetes - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Pipeline Review, H2 2017, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape. Type 2 diabetes is a chronic...

  • Biopharmaceutical
  • Pathology
  • Type 2 Diabetes
  • United States
  • Company
  • CHRONIC KIDNEY DISEASE (CHRONIC RENAL FAILURE) - PIPELINE BY GILEAD SCIENCES INC, H2 2017
  • CHRONIC KIDNEY DISEASE (CHRONIC RENAL FAILURE) - PIPELINE BY GNI GROUP LTD, H2 2017

No grade ## gastrointestinal adverse events were reported.

  • Diabetes
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative

Small molecule specifically acts on NOX## (NADPH oxidase ##) and NOX## (NADPH oxidase ##).

  • Type 2 Diabetes
  • United States
  • World
  • Product Initiative
  • GenKyoTex S.A.

Cardiac and Vascular Group The Minimally Invasive Therapies Group (MITG) includes the Surgical Innovations (SI) and the Respiratory, Gastrointestinal & Renal (RGR) divisions.

  • Clinical Trial
  • Prostate Cancer
  • Type 2 Diabetes
  • United States
  • Medtronic, Inc.
  • OMS-721 - DRUG PROFILE

It provides products across various therapeutic areas including hematology, neuroscience, immunology, genetic disease, ophthalmic, gastrointestinal, endocrine, hereditary angioedema, cancer and other diseases.

  • Autoimmune Disease
  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • ChemoCentryx, Inc.